Thus, a better understanding of the specific molecular dependencies of HER2+-BC may uncover novel therapeutic targets that have the potential to enhance the efficacy of existing therapies or provide alternative treatment approaches for this aggressive disease. This evidence concerns the gene ERBB2 and breast cancer.